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A B S T R A C T
Introduction: Pregabalin (PGB)was licensed in the EU in 2004 as an adjunctive therapy in partial epilepsy.
It is also licensed for neuropathic pain and generalised anxiety.
Aims: To identify the clinical usefulness and side effects of add-on PGB in out-patient epilepsy clinics.
Methods: We performed an audit on 96 consecutive patients (44 male) prescribed PGB for refractory
epilepsy. Mean follow-up, for those who remained on PGB, was 23 months (range 12–39 months).
Results: Fifty patients remained on PGB, 37 of whom reported clear improvement in seizure frequency.
Among these 37 patients, 1 was seizure free for 15 months; 29 had a seizure reduction of >50%; and 7
improved by <50%. Eight patients reported a decrease in seizure severity without change in seizure
frequency. Nine patients reported an incidental improvement in anxiety.
Side effects were reported by 25 patients out of the 50 patients still on treatment: 12 reported
drowsiness or tiredness, 8 weight gain, 7 dizziness, 2 headache, 2 cognitive side effects, 1 irritability, 1
itchiness, 1 anxiety, and 1 transient rash.
Among the 46 patients who discontinued treatment, 9 had worsening of seizure frequency, 27 lack of
efﬁcacy and 9 intolerable side effects necessitatingwithdrawal (4 dizziness or drowsiness, 2weight gain,
1 peripheral oedema, 1 pain in arms and legs, 1 irritability and cognitive side effects). One patient had a
seizure related death (probably drowning) within 1 month of starting PGB.
Conclusion: Pregabalin seems to be an effective andwell-tolerated anti-epileptic drugwhen used as add-
on treatment in patients with refractory partial epilepsy.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Pregabalin (PGB: (S)-3-(aminomethyl)-5-methylhexanoic
acid, CI-1008, S(+)-3-isobutyl GABA) is a new anti-epileptic drug
that was licensed in Europe in 2004 as adjunctive therapy for
partial epilepsy. Its mechanism of action in epilepsy appears, like
gabapentin, to rest upon the reduction of neurotransmitter
release at synapses, by binding to the a2-d protein, an auxiliary
subunit of voltage-gated calcium channels (for a review see Ref.
1). PGB has been reported to have a broad spectrumof action and a* Corresponding author at: Department of Clinical Neuroscience, Institute of
Psychiatry, King’s College London, De Crespigny Park, Denmark Hill, London SE5
9RS, UK. Tel.: +44 2078485161.
E-mail address: antonio.valentin@iop.kcl.ac.uk (A. Valentin).
1059-1311/$ – see front matter  2009 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2009.01.001good safety proﬁle, signiﬁcantly reducing the frequency of partial
seizures in several double-blind randomized clinical trials.2–6 The
improvement rates in these studies that included highly
refractory patients ranged between 17.4% and 39.5%. No inter-
actions with other drugs have been reported. Mild to moderate
dose-related adverse events have been reported, including
dizziness, ataxia, weight gain, somnolence, asthenia and periph-
eral oedema.
In addition to epilepsy, PGB has also been shown useful for the
treatment of pain in diabetic neuropathy,7,8 post-herpetic neur-
algia in adults,9,10 ﬁbromyalgia,11 and more recently, for the
treatment of anxiety disorders.12–16
In an early cohort of patients prescribed PGB for epilepsy in
standard out-patients clinical settings, we assessed outcome
looking at seizure freedom, improvement in seizures, retention
rate and side effects.vier Ltd. All rights reserved.
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2.1. Patients
This audit comprises the outcome of the ﬁrst 96 patients
commencing on PGB as adjunctive therapy for partial epilepsy
from the South East of UK (Kent and Canterbury Hospital, King’s
College Hospital NHS Foundation Trust, Maidstone and Tunbridge
Wells NHS Trust, Dartford and GraveshamNHS Trust, and Kent and
Medway and Social Care Partnership Trust). Only patients still on
PGB with a minimum follow-up of 12 months were considered for
this audit.
2.2. Audit method
Patients were followed up in clinic as per usual practice.
An electronic clinical database was set up with data obtained
by review of the medical notes, including seizure types,
epilepsy syndrome, aetiology, duration of epilepsy, seizure
frequency, anti-epileptic medication, both previous and
current and PGB use. There was no alteration in on-going care.
Patients were started on PGB between July 2004 and December
2006.
Response to treatment was rated as follows: seizure control
(100% seizure remission); decrease in seizures by >50% (respon-
der); decrease in seizures by <50% (partial responder); improve-
ment in seizure pattern, unchanged, or worsened seizures. All
recorded side effects were noted as well as themain reason for PGB
withdrawal.
3. Results
3.1. The cohort
There were 96 patients, 44 male and 52 female with an age
range of 21–84 years (mean 43.5). Eighty-ﬁve patients were
classiﬁed as having focal symptomatic epilepsy, 2 patients as
idiopathic generalised epilepsy (both with generalised tonic–
clonic seizures and absences), 1 had Lennox-Gastaut syndrome,
and 8 patients were unclassiﬁed (7 with generalised tonic–clonic
seizures and 1 with complex partial seizures and myoclonic jerks).
Seizures were refractory, with a median number of seizures per
month of 12 (1–400). The number of other anti-epileptic drugs,
excluding as required benzodiazepines, taken by patients at the
time of commencing PGB ranged from 0 to 4 (median 2). The
minimum number of other anti-epileptic drugs ever taken before
commencing PGB, excluding as required benzodiazepines, ranged
from 1 to 9 (median 3).Fig. 1. Retention rates on PGB shown in a survival curve (follow-up: 1 year).3.2. Follow-up and overall outcome
Among the 96 patients, 62 patients (65%) continued taking PGB
in the initial follow-up period of 12 months (Fig. 1), and among
them, 50 remained on PGB at the time of last review (up to 39
months,mean 23months). Among these 50 patients, 37 had a clear
reduction in seizure frequency, including 1 patient who was
seizure free for 15 months. Twenty-nine patients had seizure
reduction by more than 50% (responders) and 7 by less than 50%
(partial responders). Eight patients reported improvement in
seizure pattern, with less severe seizures, but without clear change
in frequency. Five patients did not show any overall reduction in
seizure frequency or any improvement in seizure severity, and PGB
is being withdrawn. Among the 50 patients remaining on PGB, 9
reported a reduction of anxiety (typically expressed as an
improvement in mood) and 7 had a reduction in the number of
other anti-epileptic drugs.
The mean maintenance dose of PGB was 187.5 mg (range 25–
600). Different titration schemes were used in different centres.
The most frequent initial dose of PGB was 25 mg twice/day or less,
with subsequent titration according to clinical effects. At
Maidstone and Tunbridge Wells NHS Trust, and at Dartford and
Gravesham NHS Trust, the initial dose of 75 mg twice/day
recommended by the manufacturers was used.
Daily doses of PGB in the seizure free patient was 450 mg.
Responders were on a mean dose of 291 mg (range 50–600) and
partial responders on 300 mg (range 100–500).
3.3. Withdrawal
Forty-six patients no longer remained on PGB. Twenty-seven
discontinued because of lack of efﬁcacy, 9 because intolerable side
effects (4 dizziness or drowsiness, 2 weight gain, 1 peripheral
oedema, 1 pain in arms and legs, 1 irritability and cognitive side
effects), 9 had worsening of seizure frequency and 1 had a seizure
related death (probably drowning) within 1 month of starting
PGB. One patient was completely seizure free for more than 6
months, but withdrew PGB due to side effects (weight gain and
pain in arms and legs). Six out of the eight patients with
unclassiﬁed epilepsy and the 2 patients with IGE withdrew PGB
due to lack of efﬁcacy.
3.4. Side effects
Side effects were generallymild tomoderate in severity. Among
the 50 patients still on treatment, 25 patients (50%) reported no
side effects at any time, 12 reported drowsiness or tiredness, 8
reported weight gain, 8 reported dizziness, 2 reported some
cognitive side effects, 2 reported headache, 1 reported irritability, 1
reported itchiness, 1 reported anxiety, and 1 reported a transient
rash. An improvement in mood was reported in nine patients.
Among the 46 patientswhowithdrewPGB, 11 patients reported
no side effects at any time, 3 reported drowsiness or tiredness, 6
reported weight gain, 5 reported dizziness, 3 reported cognitive
side effects, and 2 irritability. Other reported side effects were:
itchiness, hallucinations, nausea, worsening in memory, dry
mouth, worse postictal state, tachycardia, palpitations and pain
in limbs. An improvement in mood was reported in two patients.
Not clear synergy regarding side effects was seen between PGB and
other anti-epileptic drugs.
4. Discussion
The audit included refractory cases of epilepsy as it is based
upon the ﬁrst 96 patients to start PGB close to the time of licensing
of the drug and reﬂects experience in a clinical setting.
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of PGB provided by controlled and audit studies.4,17 We found PGB
to be efﬁcacious in this cohort of highly refractory epileptic
patients. The 65% retention rate of PGB in patients with a follow-up
of 1 year is similar to the retention rated described in other audit
studies.3 Among the 50 patients still on PGB, 30 patients showed a
clear improvement (>50%) of the seizure frequency, and another
15were partial responders or reported an improvement in severity
of seizures.
The recommended starting dose of PGB in the treatment of
epilepsy is 75 mg twice/day and, in controlled trials, upward
titration of this dose correlates with increased treatment effect.
However, initial doses of PGB in the current audit were usually
lower than those recommended as it was anticipated that initial
low doses and slow titration could minimize withdrawal. In
addition, informally we observed that a few patients with early
beneﬁt worsened on higher doses. It is possible that this reﬂects a
therapeutic window phenomenon but more data would be
required to conﬁrm this.
We conﬁrmed that PGB is generally well tolerated. Early side
effects, most commonly dizziness or drowsiness/tiredness, were
often transient, but were responsible for the withdrawn of PGB in
some cases. Among other relatively frequent side effects, weight
gain was reported in 14 patients, and was the main reason for
withdrawl of PGB in ﬁve. A positive side effect that improved
quality of lifewas reduction of anxiety; thiswas clearly reported by
11 patients, 9 of them still in PGB. Patients typically expressed this
as ‘‘improvement of mood’’, ‘‘being happier’’ or ‘‘less stress’’.
In summary, PGB seems an effective and well-tolerated AED
when used as add-on treatment in standard out-patient epilepsy
clinics. In our study we found that, with a mean follow-up of 23
months, PGB may decrease seizure frequency by more than 50% in
around 30% of the patients, and produce an improvement in the
pattern of seizures in 15% of the patients. Some responders were
able to reduce other AEDs but none achievedmonotherapy. Further
studies would be needed to assess the whether PGB might be
effective as monotherapy in similar patient groups.
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